97. Ulcerative colitis Clinical trials / Disease details
Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
Showing 1 to 3 of 3 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000037261 | 2020-10-01 | 2020-08-27 | Study on the clinic of stasis removing and renewal therapy for ulcerative colitis based on serum exosome miRNA to regulate the immune microenvironment Study on the clinic of stasisremoving and renewal therapy for ulcerative colitis based on serum exos ... | Study on the clinic of stasis removing and renewal therapy for ulcerative colitis based on serum exosome miRNA to regulate the immune microenvironment Study on the clinic of stasisremoving and renewal therapy for ulcerative colitis based on serum exos ... | Ulcerative Colitis | experimental group:stasis removing and immunoregulation therapy;control group:mesalamine; | Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Trad ... | NULL | Recruiting | 18 | 65 | Both | experimental group:30;control group:30; | China | |
| 2 | ITMCTR2000002903 | 2020-01-03 | 2020-01-05 | phase IIa clinical trial of Colitis Suppositories | A multicenter, randomized, blinded management, positive-drug parallel-controlled, preliminary exploratory phase IIa clinical trial on the efficacy and safety of Colitis Suppositories in the treatment for mild-to-moderate active ulcerative colitis (Qi-Deficiency and Blood-Stasis Syndrome), compared with the Mesalazine Suppositories (Salofalk) A multicenter, randomized, blinded management, positive-drug parallel-controlled, preliminary explor ... | mild-to-moderate active ulcerative colitis (Qi-Deficiency and Blood-Stasis Syndrome) | The control group:Mesalazine Suppositories, one at a time, twice a day, in the early and late anal plug into the rectum.;Experimental group:Colitis Suppositories, one at a time, twice a day, in the early and late anal plug into the rectum.; The control group:MesalazineSuppositories, one at a time, twice a day, in the early and late anal pl ... | Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University | NULL | Recruiting | 18 | 65 | Both | The control group:30;Experimental group:30; | Phase 2 | China |
| 3 | ChiCTR2000028869 | 2020-01-03 | 2020-01-05 | phase IIa clinical trial of Colitis Suppositories | A multicenter, randomized, blinded management, positive-drug parallel-controlled, preliminary exploratory phase IIa clinical trial on the efficacy and safety of Colitis Suppositories in the treatment for mild-to-moderate active ulcerative colitis (Qi-Deficiency and Blood-Stasis Syndrome), compared with the Mesalazine Suppositories (Salofalk) A multicenter, randomized, blinded management, positive-drug parallel-controlled, preliminary explor ... | mild-to-moderate active ulcerative colitis (Qi-Deficiency and Blood-Stasis Syndrome) | Experimental group:Colitis Suppositories, one at a time, twice a day, in the early and late anal plug into the rectum.;The control group:Mesalazine Suppositories, one at a time, twice a day, in the early and late anal plug into the rectum.; Experimental group:Colitis Suppositories, one at a time, twice a day, in the early and late anal plu ... | Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University | NULL | Recruiting | 18 | 65 | Both | Experimental group:30;The control group:30; | Phase 2 | China |